乐
乐观
乐观 · 25%MAZE
$21.54
情景价格
$32.580
+0.130 (+0.40%)收盘时
Loading chart…
- 最高
- 33.005
- 开盘
- 32.385
- 成交量加权均价
- 32.38
- 成交量
- 1.07M
- 市值
- —
- 最低
- 31.555
- 成交额
- 34.59M
- 企业价值/息税折旧摊销前利润（TTM）
- -26.39
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
AI 分析 of Maze Therapeutics Inc (MAZE)
买入Maze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
估值指标
Maze Therapeutics Inc（MAZE）当前预期市盈率为 8.53，5 年平均预期市盈率为 1.45。
Alphio AI 对 MAZE 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
持有 MAZE 的大户
事件时间线
资讯
MAZE 常见问题 —— 由 Alphio AI 解答
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target. It operates in the Healthcare sector.
Maze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
社区
更多 ↗暂无帖子
注册或登录后参与讨论本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。